Methylprednisolone 500 mg powder and solvent for solution for injection/infusion
Sponsors
F. Hoffmann-La Roche AG, Assistance Publique Hopitaux De Paris
Conditions
Multiple sclerosis (MS)Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)Primary Progressive Multiple Sclerosis (PPMS)Progressive multiple sclerosis (PMS)Relapsing Multiple Sclerosis (MS)Relapsing-Remitting Multiple Sclerosis (RRMS)
Phase 2
Phase 3
A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial
CompletedCTIS2023-506543-41-00
Start: 2018-07-25End: 2025-04-22Target: 645Updated: 2025-06-16
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Active, not recruitingCTIS2023-506467-34-00
Start: 2020-10-20Target: 357Updated: 2025-11-17
A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis
Active, not recruitingCTIS2023-506515-18-00
Start: 2020-10-23Target: 310Updated: 2025-03-26
An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis
Active, not recruitingCTIS2023-506429-13-00
Start: 2018-05-02Target: 520Updated: 2025-08-25
COTAM - Use of glucocorticoids therapy in acute myocarditis with severe left ventricular dysfunction: a multicenter randomized controlled trial
Not yet recruitingCTIS2024-510602-90-00
Target: 420Updated: 2025-08-04